Edwards Lifesciences (EW) Reports In-Line Q4 EPS, Q1 EPS Guidance Comes in Light
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Edwards Lifesciences (EW) PT Raised to $186 at Raymond James
February 1, 2019 7:47 AM ESTRaymond James analyst Jayson Bedford raised the price target on Edwards Lifesciences (NYSE: EW) to $186.00 (from $175.00) while maintaining a Outperform rating.
... MoreEdwards Lifesciences (EW) PT Raised to $175 at UBS
February 1, 2019 7:15 AM ESTUBS analyst Matthew Taylor raised the price target on Edwards Lifesciences (NYSE: EW) to $175.00 (from $165.00) while maintaining a Neutral rating.
... MoreEdwards Lifesciences (EW) PT Raised to $182 at RBC Capital
February 1, 2019 6:42 AM ESTRBC Capital analyst Glenn Novarro raised the price target on Edwards Lifesciences (NYSE: EW) to $182.00 (from $175.00) while maintaining a Outperform rating.
Novarro commented, "Revenue guidance for 1Q19, implying high-single-digit CC growth at the midpoint, adequately captures competitive dynamics in the TAVR market.... More
